Unveiling changes in the landscape of patient populations in cancer early drug development

The introduction of new Molecularly Targeted Agents (MTA) has changed the landscape in Early Drug Development (EDD) over the last two decades, leading to an improvement in clinical trial design. Previous Phase 1 (Ph1) studies with cytotoxics focused on safety objectives, only recruiting heavily pre-...

Descripción completa

Detalles Bibliográficos
Autores principales: Hierro, Cinta, Azaro, Analía, Argilés, Guillem, Elez, Elena, Gómez, Patricia, Carles, Joan, Rodon, Jordi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355170/
https://www.ncbi.nlm.nih.gov/pubmed/27835915
http://dx.doi.org/10.18632/oncotarget.13258

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355170/
https://www.ncbi.nlm.nih.gov/pubmed/27835915
http://dx.doi.org/10.18632/oncotarget.13258

Ejemplares similares